GlassScriptPhysician profile
Arvind K Bansal
NPI 1962523381
$3,732.51
in general payments reported to CMS, 2019-2025
37 companies · $1,035 in 2025
The $1,035 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $393 · 2020: $258 · 2021: $210 · 2022: $373 · 2023: $640 · 2024: $824 · 2025: $1,035.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,319 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,319.22 |
| Education | $179.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $544.68 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $324.87 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| Harmony Biosciences LLC | $222.53 | 2020-2025 | |
| Genzyme Corporation | $208.79 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $206.16 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $176.75 | 2020-2025 | Fasenra |
| Regeneron Healthcare Solutions, INC. | $164.14 | 2019-2024 | Dupixent |
| Grifols USA, LLC | $162.20 | 2019-2025 | Prolastin-C Liquid |
| Insmed, INC. | $154.60 | 2023-2025 | Arikayce |
| Mylan Specialty L.P. | $151.13 | 2019-2024 | Yupelri |
| Zoll Respicardia, INC. | $124.51 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $113.31 | 2020-2022 | |
| Genentech USA, INC. | $112.53 | 2020-2023 | Xolair |
| Axsome Therapeutics, INC. | $93.08 | 2023-2025 | Sunosi |
| United Therapeutics Corporation | $90.74 | 2022-2024 | Tyvaso |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $87.87 | 2025 | Yupelri |
| Mallinckrodt Hospital Products INC. | $76.16 | 2023 | Acthar |
| Merck Sharp & Dohme LLC | $71.92 | 2019-2025 | Zerbaxa, Belsomra |
| Verona Pharma, INC. | $70.53 | 2025 | Ohtuvayre |
| Amgen INC. | $64.61 | 2025 | Tezspire |
| Baxter Healthcare | $50.11 | 2023-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Gilead Sciences, INC. | $46.74 | 2022-2024 | |
| Actelion Pharmaceuticals US, INC. | $42.91 | 2023-2024 | Uptravi, Opsumit |
| Resmed Corp | $39.42 | 2023 | |
| Abbvie INC. | $39.32 | 2022-2025 | |
| Inspire Medical Systems, INC. | $38.18 | 2023 | Inspire |
| Pulmonx Corporation | $35.36 | 2023 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Veran Medical Technologies, INC. | $35.00 | 2019 | |
| Paratek Pharmaceuticals, INC. | $31.06 | 2023 | Nuzyra |
| Vifor Pharma, INC. | $27.01 | 2025 | Zemaira |
| Csl Behring | $26.34 | 2025 | Kcentra |
| Inogen, INC. | $18.92 | 2024 | |
| Lilly USA, LLC | $18.62 | 2025 | Zepbound |
| Avadel Cns Pharmaceuticals, LLC | $16.82 | 2024 | Lumryz |
| Boston Scientific Corporation | $15.61 | 2024 | |
| Fisher & Paykel Healthcare INC | $15.25 | 2019 | |
| Idorsia Pharmaceuticals US INC | $14.73 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arvind Bansal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.